Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy

Victoria M Addis, Eydie Miller-Ellis Division of Glaucoma, Scheie Eye Institute, University of Pennsylvania, Philadelphia, PA, USAAbstract: Latanoprostene bunod (LBN) 0.024%, a modified prostaglandin analog, was approved on November 2, 2017, for the reduction of IOP in patients with open-angle glauc...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Addis VM, Miller-Ellis E
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Latanoprostene bunod open angle glaucoma ocular hypertension modified prostaglandin analog nitric oxide treatment-associated adverse event Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/c9383bc0ee124c8e94cd9995197c5860
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c9383bc0ee124c8e94cd9995197c5860
record_format	dspace
spelling	oai:doaj.org-article:c9383bc0ee124c8e94cd9995197c58602021-12-02T02:47:49ZLatanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy1177-5483https://doaj.org/article/c9383bc0ee124c8e94cd9995197c58602018-12-01T00:00:00Zhttps://www.dovepress.com/latanoprostene-bunod-ophthalmic-solution-0024-in-the-treatment-of-open-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Victoria M Addis, Eydie Miller-Ellis Division of Glaucoma, Scheie Eye Institute, University of Pennsylvania, Philadelphia, PA, USAAbstract: Latanoprostene bunod (LBN) 0.024%, a modified prostaglandin analog, was approved on November 2, 2017, for the reduction of IOP in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). LBN works by combining the IOP-lowering effects of the prostaglandin analogs (through the uveoscleral pathway) with nitric oxide-induced relaxation of the trabecular meshwork and Schlemm’s canal. Nitric oxide-induced relaxation of the trabecular meshwork and Schlemm’s canal leads to increased outflow through the trabecular meshwork and thus lowering of IOP. LBN has now been shown in multiple clinical studies to be effective and safe. In this article, we summarize the clinical trials that led to LBN’s approval as well as the comparative studies that have been done to evaluate the efficacy of this drug as compared to other US Food and Drug Administration (FDA)-approved therapies for OAG and OHT. We then review the side effects of treatment that were seen in each of these studies. Finally, we will attempt to discuss the place of this drug in therapy for patients with OAG. Keywords: latanoprostene bunod, open-angle glaucoma, ocular hypertension, modified prostaglandin analog, nitric oxide, treatment-associated adverse eventAddis VMMiller-Ellis EDove Medical PressarticleLatanoprostene bunodopen angle glaucomaocular hypertensionmodified prostaglandin analognitric oxidetreatment-associated adverse eventOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 12, Pp 2649-2657 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Latanoprostene bunod open angle glaucoma ocular hypertension modified prostaglandin analog nitric oxide treatment-associated adverse event Ophthalmology RE1-994
spellingShingle	Latanoprostene bunod open angle glaucoma ocular hypertension modified prostaglandin analog nitric oxide treatment-associated adverse event Ophthalmology RE1-994 Addis VM Miller-Ellis E Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy
description	Victoria M Addis, Eydie Miller-Ellis Division of Glaucoma, Scheie Eye Institute, University of Pennsylvania, Philadelphia, PA, USAAbstract: Latanoprostene bunod (LBN) 0.024%, a modified prostaglandin analog, was approved on November 2, 2017, for the reduction of IOP in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). LBN works by combining the IOP-lowering effects of the prostaglandin analogs (through the uveoscleral pathway) with nitric oxide-induced relaxation of the trabecular meshwork and Schlemm’s canal. Nitric oxide-induced relaxation of the trabecular meshwork and Schlemm’s canal leads to increased outflow through the trabecular meshwork and thus lowering of IOP. LBN has now been shown in multiple clinical studies to be effective and safe. In this article, we summarize the clinical trials that led to LBN’s approval as well as the comparative studies that have been done to evaluate the efficacy of this drug as compared to other US Food and Drug Administration (FDA)-approved therapies for OAG and OHT. We then review the side effects of treatment that were seen in each of these studies. Finally, we will attempt to discuss the place of this drug in therapy for patients with OAG. Keywords: latanoprostene bunod, open-angle glaucoma, ocular hypertension, modified prostaglandin analog, nitric oxide, treatment-associated adverse event
format	article
author	Addis VM Miller-Ellis E
author_facet	Addis VM Miller-Ellis E
author_sort	Addis VM
title	Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy
title_short	Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy
title_full	Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy
title_fullStr	Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy
title_full_unstemmed	Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy
title_sort	latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/c9383bc0ee124c8e94cd9995197c5860
work_keys_str_mv	AT addisvm latanoprostenebunodophthalmicsolution0024inthetreatmentofopenangleglaucomadesigndevelopmentandplaceintherapy AT millerellise latanoprostenebunodophthalmicsolution0024inthetreatmentofopenangleglaucomadesigndevelopmentandplaceintherapy
_version_	1718402188055674880

Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy

Ejemplares similares